PE20020271A1 - Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester - Google Patents
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril esterInfo
- Publication number
- PE20020271A1 PE20020271A1 PE2001000773A PE2001000773A PE20020271A1 PE 20020271 A1 PE20020271 A1 PE 20020271A1 PE 2001000773 A PE2001000773 A PE 2001000773A PE 2001000773 A PE2001000773 A PE 2001000773A PE 20020271 A1 PE20020271 A1 PE 20020271A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- chain
- transfer protein
- protein inhibitors
- cholesteryl ester
- Prior art date
Links
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229920000642 polymer Polymers 0.000 abstract 3
- -1 3,5-DICHLORO-BENZYL Chemical class 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical class C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical class [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- DXHPZXWIPWDXHJ-UHFFFAOYSA-N carbon monosulfide Chemical class [S+]#[C-] DXHPZXWIPWDXHJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical class S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 abstract 1
- 229920006163 vinyl copolymer Polymers 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION QUE COMPRENDE UNA DISPERSION AMORFA HOMOGENEA DE SOLIDOS DE a)INHIBIDORES DE PROTEINA DE TRANSFERENCIA DE COLESTERIL ESTER QUE TIENE UNA SOLUBILIDAD EN SOLUCION ACUOSA MENOR DE 10µg/ml EN AUSENCIA DE DICHO POLIMERO QUE AUMENTA LA CONCENTRACION MENOR DE 10µg/ml; A CUALQUIER pH DE 1-8; LA PORCION PRINCIPAL ES AMORFA; TIENE UN CLOGP MAYOR DE 4; TAL COMO i)UN COMPUESTO DE FORMULA I DONDE R1-1 ES H, Y1, W1-X1; W1-Y1; W1 ES CARBONILO, TIOCARBONILO, SULFINILO, SULFONILO; X1-O-Y1, S-Y1, NH-Y1, N-(Y1)2; Y1 ES Z1, CADENA CARBONADA; R1-3 ES H, Q1; Q1 ES UNA CADENA CARBONADA; R1-4 ES Q1-1, V1-1; Q1-1 ES UNA CADENA CARBONADA; V1-1 ES UN ANILLO DE 3-7 MIEMBROS; R1-3 CONTIENE V1; R1-4 CONTIENE V1-1; R1-5, R1-6, R1-7, R1-8 ES H, OH, OXI; ii)4-CARBOXIAMINO-2-METIL-1,2,3,4-TETRAHIDROQUINOLINAS; ENTRE OTROS. SON COMPUESTOS PREFERIDOS ESTER ETILICO DEL ACIDO [2R,4S]-4-[(3,5-DICLORO-BENCIL)-METOXICARBONIL-AMINO]6,7-DIMETOXI-2-METIL-3,4-DIHIDRO-2H-QUINOLINA-1-CARBOXILICO, ESTER ETILICO DEL ACIDO [2R,4S]-4-[(3,5-DINITRO-BENCIL)-METOXICARBONIL-AMINO]-6,7-DIMETOXI-2-METIL-3,4-DIHIDRO-2H-QUINOLINA-1-CARBOXILICO, ENTRE OTROS; b)UN POLIMERO QUE AUMENTA LA CONCENTRACION DE PREFERENCIA POLIMEROS CELULOSICOS IONIZABLES Y NO IONIZABLES; POLIMEROS Y COPOLIMEROS DE VINILO; LA COMPOSICION SE CARACTERIZA PORQUE LA RELACION ENTRE LA DOSIS Y LA SOLUBILIDAD EN AGUA ES DE AL MENOS 1000ml Y PUEDE SER UTIL PARA EL TRATAMIENTO DE ATEROSCLEROSIS, ENFERMEDAD VASCULAR PERIFERICA, DISLIPIDEMIA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22327900P | 2000-08-03 | 2000-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020271A1 true PE20020271A1 (es) | 2002-04-08 |
Family
ID=22835821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000773A PE20020271A1 (es) | 2000-08-03 | 2001-08-02 | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester |
Country Status (39)
| Country | Link |
|---|---|
| US (4) | US7115279B2 (es) |
| EP (2) | EP2258352B1 (es) |
| JP (2) | JP2004505911A (es) |
| KR (1) | KR100561572B1 (es) |
| CN (1) | CN1458840A (es) |
| AP (1) | AP2001002235A0 (es) |
| AR (1) | AR030570A1 (es) |
| AT (1) | ATE503462T1 (es) |
| AU (1) | AU2914202A (es) |
| BG (1) | BG107456A (es) |
| BR (1) | BR0112828A (es) |
| CA (1) | CA2417755A1 (es) |
| CR (1) | CR6883A (es) |
| CZ (1) | CZ2003224A3 (es) |
| DE (1) | DE60144332D1 (es) |
| DO (1) | DOP2001000224A (es) |
| DZ (1) | DZ3391A1 (es) |
| EA (1) | EA007013B1 (es) |
| EC (1) | ECSP034462A (es) |
| EE (1) | EE200300052A (es) |
| GT (1) | GT200100156A (es) |
| HN (1) | HN2001000175A (es) |
| HU (1) | HUP0300676A2 (es) |
| IL (1) | IL154017A0 (es) |
| IS (1) | IS6688A (es) |
| MA (1) | MA26935A1 (es) |
| MX (1) | MXPA03001035A (es) |
| NO (1) | NO20030506D0 (es) |
| NZ (1) | NZ523680A (es) |
| OA (1) | OA12350A (es) |
| PA (1) | PA8523901A1 (es) |
| PE (1) | PE20020271A1 (es) |
| PL (1) | PL365168A1 (es) |
| SK (1) | SK1032003A3 (es) |
| SV (1) | SV2002000581A (es) |
| TN (1) | TNSN01119A1 (es) |
| UY (1) | UY26864A1 (es) |
| WO (1) | WO2002011710A2 (es) |
| ZA (1) | ZA200300869B (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| DE10063486A1 (de) * | 2000-12-20 | 2002-07-04 | Bayer Ag | Dichlorpyridylmethylamide |
| EE200400024A (et) * | 2001-06-21 | 2004-06-15 | Pfizer Products Inc. | Kolesterüülestri ülekandevalgu inhibiitorite iseemulgeeruvad formulatsioonid |
| WO2003000226A2 (en) * | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions containing polymer and drug assemblies |
| WO2003000235A1 (en) * | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions of dispersions of drugs and neutral polymers |
| NZ529490A (en) * | 2001-06-22 | 2005-08-26 | Pfizer Prod Inc | Pharmaceutical compositions of adsorbates of amorphous drug |
| HUP0400264A2 (hu) * | 2001-06-22 | 2004-08-30 | Pfizer Products Inc. | Alacsony oldékonyságú és/vagy savra érzékeny hatóanyagokat és semlegesített savas polimereket tartalmazó gyógyszerkészítmények és eljárás az előállításukra |
| WO2003000294A1 (en) * | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer |
| EP1469830A2 (en) * | 2002-02-01 | 2004-10-27 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles |
| ES2305434T3 (es) | 2002-02-01 | 2008-11-01 | Pfizer Products Inc. | Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas. |
| EP1474144B1 (en) | 2002-02-01 | 2008-08-06 | Pfizer Products Inc. | Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor |
| AR038375A1 (es) * | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
| BR0307516A (pt) * | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Formas de dosagem de liberação imediata contendo dispersões de uma droga sólida |
| WO2003063822A2 (en) | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| CN1681479A (zh) | 2002-08-12 | 2005-10-12 | 辉瑞产品公司 | 半有序药物和聚合物的药物组合物 |
| EA011385B1 (ru) | 2002-10-04 | 2009-02-27 | Миллениум Фармасьютикалз, Инк. | Антагонисты рецептора pgd2 для лечения воспалительных заболеваний |
| US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
| CA2508840A1 (en) | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
| KR20050088190A (ko) * | 2002-12-20 | 2005-09-02 | 화이자 프로덕츠 인코포레이티드 | 콜레스테릴 에스터 전달 단백질 억제제 및 ｈｍｇ-ｃｏａ환원 효소 억제제를 포함하는 투약 형태 |
| JP2006520810A (ja) * | 2003-03-17 | 2006-09-14 | 日本たばこ産業株式会社 | Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートの経口吸収性を増加させる方法 |
| CN1761463A (zh) * | 2003-03-17 | 2006-04-19 | 日本烟草产业株式会社 | 提高s－[2－([[1－(2－乙基丁基)环己基]羰基]氨基)苯基]－2－甲基丙硫代酸酯口服生物利用度的方法 |
| ATE534381T1 (de) * | 2003-03-17 | 2011-12-15 | Japan Tobacco Inc | Pharmazeutische cetp-inhibitor-zusammensetzungen |
| TWI393560B (zh) * | 2003-05-02 | 2013-04-21 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| BRPI0413363A (pt) * | 2003-08-04 | 2006-10-10 | Pfizer Prod Inc | formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase |
| CA2532931A1 (en) * | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
| CL2004001884A1 (es) * | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
| EP2319509A1 (en) * | 2003-09-26 | 2011-05-11 | Japan Tobacco, Inc. | Method of Inhibiting remnant lipoprotein production |
| BRPI0414671A (pt) * | 2003-09-30 | 2006-11-21 | Pfizer Prod Inc | inibidores da cetp e metabolitos dos mesmos |
| ES2332051T3 (es) * | 2003-10-08 | 2010-01-25 | Eli Lilly And Company | Compuestos y procedimientos para tratar dislipidemia. |
| SI1759702T1 (sl) * | 2004-05-26 | 2009-06-30 | Bayardo Arturo Jimenez | Postopek pripravljanja oftalmiäśne raztopine latanoprosta in tako proizvedena raztopina |
| WO2006069162A1 (en) | 2004-12-20 | 2006-06-29 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds and their pharmaceutical compositions |
| US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| US9040558B2 (en) | 2004-12-31 | 2015-05-26 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| CA2601762A1 (en) * | 2005-02-03 | 2006-08-10 | Pfizer Products Inc. | Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| EP1861372A1 (en) | 2005-02-24 | 2007-12-05 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| JP2009514884A (ja) * | 2005-11-04 | 2009-04-09 | イーストマン ケミカル カンパニー | 難溶性医薬活性剤の投与のためのカルボキシアルキルセルロースエステル |
| BRPI0707584A2 (pt) * | 2006-02-09 | 2011-05-10 | Merck & Co Inc | composiÇço farmacÊutica, uso da composiÇço farmacÊutica, e, formulaÇço farmacÊutica |
| PE20081506A1 (es) * | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | Formulaciones de ansamicina |
| EP1997819A1 (de) | 2007-05-25 | 2008-12-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Herstellung von Scopinestern |
| US8337835B2 (en) * | 2009-04-10 | 2012-12-25 | Washington University | Use of an endogenous ligand for peroxisome proliferator activated receptor alpha to treat liver disorders |
| SMT202000093T1 (it) | 2009-06-16 | 2020-03-13 | Pfizer | Forme di dosaggio di apixaban |
| BR112013021030A2 (pt) | 2011-02-17 | 2016-10-11 | Hoffmann La Roche | processo para cristalização controlada de um ingrediente farmacêutico ativo a partir de estado líquido super-refrigerado por extrusão por fusão a quente |
| US8591944B2 (en) | 2011-03-08 | 2013-11-26 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
| US9199967B2 (en) | 2011-08-18 | 2015-12-01 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors |
| IN2014CN02290A (es) | 2011-09-27 | 2015-06-19 | Reddys Lab Ltd Dr | |
| CA2891502A1 (en) * | 2012-11-19 | 2014-05-22 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions of cetp inhibitors |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3871866D1 (de) | 1987-07-17 | 1992-07-16 | Dow Corning | Haertbare zusammensetzung. |
| JP2528706B2 (ja) | 1988-05-30 | 1996-08-28 | ゼリア新薬工業株式会社 | ジヒドロピリジン化合物の製剤組成物 |
| US5093371A (en) | 1990-07-02 | 1992-03-03 | University Of Iowa Research Foundation | Naphthyl ketone inhibitors of cholesterol esterase and their use as hypolipidemic and hypocaloric agents |
| JP2527107B2 (ja) | 1991-04-16 | 1996-08-21 | 日本新薬株式会社 | 固体分散体の製造方法 |
| US5340591A (en) * | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| US5446207A (en) | 1993-09-01 | 1995-08-29 | Harbor Branch Oceanographic Institution, Inc. | Anti-dyslipidemic agents |
| US5474993A (en) | 1994-06-14 | 1995-12-12 | Sterling Winthrop, Inc. | Lactam inhibitors of cholesterol esterase |
| KR100204738B1 (ko) | 1994-11-12 | 1999-06-15 | 성재갑 | 콜레스테릴 에스테르 전달 단백질 저해 펩티드 및 이를 포함하는 동맥경화증 예방 및 치료제 |
| AU4314196A (en) * | 1994-12-21 | 1996-07-10 | Yamanouchi Pharmaceutical Co., Ltd. | Solid composition with improved solubility and absorbability |
| TW487582B (en) * | 1995-08-11 | 2002-05-21 | Nissan Chemical Ind Ltd | Method for converting sparingly water-soluble medical substance to amorphous state |
| GB2305665A (en) | 1995-09-26 | 1997-04-16 | Merck & Co Inc | Selective ß3 agonists for the treatment of diabetes aand obesity |
| DE19610932A1 (de) | 1996-03-20 | 1997-09-25 | Bayer Ag | 2-Aryl-substituierte Pyridine |
| EP0801060A1 (en) | 1996-04-09 | 1997-10-15 | Pfizer Inc. | Heterocyclic Beta-3 Adrenergenic Agonists |
| HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
| DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
| AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| JP3290962B2 (ja) * | 1997-02-12 | 2002-06-10 | 日本たばこ産業株式会社 | Ｃｅｔｐ活性阻害剤 |
| JP2894445B2 (ja) * | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Ｃｅｔｐ活性阻害剤として有効な化合物 |
| DE19709125A1 (de) | 1997-03-06 | 1998-09-10 | Bayer Ag | Substituierte Chinoline |
| JPH10287662A (ja) | 1997-04-08 | 1998-10-27 | Kitasato Inst:The | Ｆｏ−５６３７ａ物質及びｂ物質並びにそれらの製造法 |
| DE69824901D1 (de) | 1997-04-16 | 2004-08-05 | Univ New Mexico Albuquerque | Cholesterin Esterase Inhibitoren |
| US5955475A (en) * | 1997-06-30 | 1999-09-21 | Endo Pharmaceuticals Inc. | Process for manufacturing paroxetine solid dispersions |
| ATE364374T1 (de) * | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| AU9297798A (en) | 1997-09-16 | 1999-04-05 | G.D. Searle & Co. | Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity |
| DE19741051A1 (de) | 1997-09-18 | 1999-03-25 | Bayer Ag | Hetero-Tetrahydrochinoline |
| MA24643A1 (fr) | 1997-09-18 | 1999-04-01 | Bayer Ag | Tetrahydro-naphtalenes substitues et composes analogues |
| DE19741399A1 (de) * | 1997-09-19 | 1999-03-25 | Bayer Ag | Tetrahydrochinoline |
| WO1999041237A1 (en) | 1998-02-13 | 1999-08-19 | G.D. Searle & Co. | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity |
| JP3433417B2 (ja) * | 1998-04-02 | 2003-08-04 | トヨタ自動車株式会社 | レーダ装置 |
| WO1999063970A1 (en) | 1998-06-11 | 1999-12-16 | Pharmacia & Upjohn Company | Delavirdine tablet formulation |
| US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| US6147090A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| US6140342A (en) * | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
| EP1589000A3 (en) | 1998-09-25 | 2006-03-15 | Monsanto Company | (R)-Chiral halogenated 1-substitutedamino-(N+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity |
| AU6161099A (en) | 1998-09-25 | 2000-04-17 | Monsanto Company | Substituted n-aliphatic-n-aromatic (tertiary)-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
| ES2307482T3 (es) | 1999-02-10 | 2008-12-01 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas. |
| US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
| CN1139660C (zh) | 1999-03-08 | 2004-02-25 | 社团法人北里研究所 | Wk-5344a物质和wk-5344b物质及其生产 |
| US6465011B2 (en) | 1999-05-29 | 2002-10-15 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
| US20010018446A1 (en) | 1999-09-23 | 2001-08-30 | G.D. Searle & Co. | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
| CO5271716A1 (es) | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
| EA004370B1 (ru) * | 1999-12-23 | 2004-04-29 | Пфайзер Продактс Инк. | Лекарственная форма с высвобождением лекарства под действием гидрогеля |
| US20010028895A1 (en) | 2000-02-04 | 2001-10-11 | Bisgaier Charles L. | Methods of treating alzheimer's disease |
| US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| HUP0400264A2 (hu) | 2001-06-22 | 2004-08-30 | Pfizer Products Inc. | Alacsony oldékonyságú és/vagy savra érzékeny hatóanyagokat és semlegesített savas polimereket tartalmazó gyógyszerkészítmények és eljárás az előállításukra |
| WO2003000235A1 (en) | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions of dispersions of drugs and neutral polymers |
| WO2003000226A2 (en) | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions containing polymer and drug assemblies |
| AR038375A1 (es) * | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
| WO2003063822A2 (en) | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| KR20050088190A (ko) * | 2002-12-20 | 2005-09-02 | 화이자 프로덕츠 인코포레이티드 | 콜레스테릴 에스터 전달 단백질 억제제 및 ｈｍｇ-ｃｏａ환원 효소 억제제를 포함하는 투약 형태 |
-
2001
- 2001-07-30 US US09/918,127 patent/US7115279B2/en not_active Expired - Fee Related
- 2001-07-31 HU HU0300676A patent/HUP0300676A2/hu unknown
- 2001-07-31 EA EA200300073A patent/EA007013B1/ru not_active IP Right Cessation
- 2001-07-31 EE EEP200300052A patent/EE200300052A/xx unknown
- 2001-07-31 KR KR1020037001456A patent/KR100561572B1/ko not_active Expired - Fee Related
- 2001-07-31 SV SV2001000581A patent/SV2002000581A/es not_active Application Discontinuation
- 2001-07-31 MX MXPA03001035A patent/MXPA03001035A/es active IP Right Grant
- 2001-07-31 NZ NZ523680A patent/NZ523680A/en unknown
- 2001-07-31 SK SK103-2003A patent/SK1032003A3/sk not_active Application Discontinuation
- 2001-07-31 CZ CZ2003224A patent/CZ2003224A3/cs unknown
- 2001-07-31 DE DE60144332T patent/DE60144332D1/de not_active Expired - Lifetime
- 2001-07-31 JP JP2002517047A patent/JP2004505911A/ja active Pending
- 2001-07-31 OA OA1200300022A patent/OA12350A/en unknown
- 2001-07-31 CN CN01815834A patent/CN1458840A/zh active Pending
- 2001-07-31 EP EP20100180614 patent/EP2258352B1/en not_active Expired - Lifetime
- 2001-07-31 EP EP01984472A patent/EP1305007B1/en not_active Expired - Lifetime
- 2001-07-31 AU AU2914202A patent/AU2914202A/xx not_active Withdrawn
- 2001-07-31 IL IL15401701A patent/IL154017A0/xx unknown
- 2001-07-31 CA CA002417755A patent/CA2417755A1/en not_active Abandoned
- 2001-07-31 AT AT01984472T patent/ATE503462T1/de not_active IP Right Cessation
- 2001-07-31 DZ DZ013391A patent/DZ3391A1/xx active
- 2001-07-31 WO PCT/IB2001/001391 patent/WO2002011710A2/en not_active Ceased
- 2001-07-31 PL PL01365168A patent/PL365168A1/xx unknown
- 2001-07-31 BR BR0112828-0A patent/BR0112828A/pt not_active IP Right Cessation
- 2001-08-01 GT GT200100156A patent/GT200100156A/es unknown
- 2001-08-01 DO DO2001P000224A patent/DOP2001000224A/es unknown
- 2001-08-01 UY UY26864A patent/UY26864A1/es not_active Application Discontinuation
- 2001-08-02 TN TNTNSN01119A patent/TNSN01119A1/fr unknown
- 2001-08-02 AR ARP010103694A patent/AR030570A1/es unknown
- 2001-08-02 AP APAP/P/2001/002235A patent/AP2001002235A0/en unknown
- 2001-08-02 PE PE2001000773A patent/PE20020271A1/es not_active Application Discontinuation
- 2001-08-03 PA PA20018523901A patent/PA8523901A1/es unknown
- 2001-08-06 HN HN2001000175A patent/HN2001000175A/es unknown
-
2003
- 2003-01-13 BG BG107456A patent/BG107456A/bg unknown
- 2003-01-16 CR CR6883A patent/CR6883A/es not_active Application Discontinuation
- 2003-01-16 IS IS6688A patent/IS6688A/is unknown
- 2003-01-23 MA MA27010A patent/MA26935A1/fr unknown
- 2003-01-31 NO NO20030506A patent/NO20030506D0/no not_active Application Discontinuation
- 2003-01-31 ZA ZA200300869A patent/ZA200300869B/en unknown
- 2003-02-03 EC EC2003004462A patent/ECSP034462A/es unknown
-
2006
- 2006-06-02 US US11/421,888 patent/US8048452B2/en not_active Expired - Fee Related
-
2007
- 2007-04-30 US US11/799,447 patent/US8197848B2/en not_active Expired - Fee Related
- 2007-08-09 JP JP2007208058A patent/JP2007314573A/ja active Pending
-
2012
- 2012-06-12 US US13/494,668 patent/US8389011B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020271A1 (es) | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester | |
| BR0108816A (pt) | Derivados de quinolina como antagonistas alfa-2 | |
| EA200400154A1 (ru) | Новые лекарственные формы замещенного бензимидазола и способ их применения | |
| YU50401A (sh) | Farmaceutski sastav koji sadrži inhibitore protonske pumpe | |
| ATE275378T1 (de) | Wässrige kosmetische gele | |
| BR0113757A (pt) | Derivados de quinolinona como inibibores de tirosina quinase | |
| BR0315547A (pt) | Derivados de quinolina como antagonistas de crth2 | |
| ATE252529T1 (de) | Colchinolderivate als gefässschädigende mittel | |
| EA200700389A1 (ru) | Стабильный при хранении инфузионный раствор дигидроптеридинонов | |
| ATE486587T1 (de) | Formulierungen zur oralen verabreichung von wirkstoffen | |
| PE20040071A1 (es) | Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion | |
| AR019150A1 (es) | Composicion farmaceutica estabilizada que contiene un componente de droga que comprende un componente de droga que comprende un inhibidor de ace, unestabilizador y un agente de minimizacion de hidrolisis, tableta que la contiene y proceso para estabilizar una droga | |
| NO20062905L (no) | Nye hydroksaminsyreestere og farmasoytisk anvendelse derav | |
| DE602004019049D1 (de) | Stabile feste medizinische zusammensetzung für die orale verabreichung von ramosetron | |
| SE9904413D0 (sv) | Comminuted form | |
| DK1458393T3 (da) | Substituerede diketopiperaziner som oxytocinantagonister | |
| BR0315662A (pt) | Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona | |
| KR100215533B1 (ko) | 아르기닌 아미드 함유 의약 조성물 | |
| DE69925270D1 (de) | Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten | |
| BR9808722A (pt) | Composições farmacêuticas de tizoxanida e nitazoxanida | |
| JP5984531B2 (ja) | 水性眼科組成物 | |
| BR0308576A (pt) | Compostos: composições farmacêuticas para administração em um mamìfero e métodos para inibir a enzima citocroma p450rai em um mamìfero | |
| AU2001246999A1 (en) | New neurokinin antagonists for use as medicaments | |
| PT1218401E (pt) | 4-benzilaminoquinolinas conjugadas com acido biliar e seus heterociclicos metodos de sua producao medicamentos contendo estes compostos e sua aplicacao | |
| SE9904412D0 (sv) | Comminuted form |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |